

Human plasma inositol hexakisphosphate (InsP₆) phosphatase identified as the Multiple Inositol Polyphosphate Phosphatase 1 (MINPP1)

Valeria Fedeli¹, Jingyi Wang¹, Vincent Cantagrel², Adolfo Saiardi^{1§}

¹Laboratory for Molecular Cell Biology, London WC1E 6BT, UK, University College London, London, England, United Kingdom

²Developmental Brain Disorders Laboratory, Université Paris Cité, INSERM UMR1163, Imagine Institute, 75015, Paris, France, Université Paris Cité, Paris, Île-de-France, France

[§]To whom correspondence should be addressed: a.saiardi@ucl.ac.uk

Abstract

Inositol hexakisphosphate (InsP₆), also known as phytic acid, is a potent chelator of bivalent cations. Intracellular InsP₆ molecules are associated with magnesium. Calcium is the prevalent bivalent cation outside the cell and its association with InsP₆ could lead to the formation of insoluble complexes. To avoid the formation of dangerous InsP₆/Calcium precipitates in the bloodstream, mammals must possess a robust InsP₆ phosphatase in their plasma. Here we identify the Multiple Inositol Polyphosphate Phosphatase 1 ([MINPP1](#)) as the InsP₆ phosphatase present in human plasma.




Figure 1. Identification of Minpp1 as the plasma InsP₆ phosphatase preventing InsP₆ precipitation.:

A) The indicated amount of InsP_6 was added to 1 ml of Ringer's solution (147 mM NaCl, 4 mM KCl, 3 mM CaCl_2) Krebs-Ringer's solution (120 mM NaCl, 5 mM KCl, 2 mM CaCl_2 , 1 mM MgCl_2 , 25 mM NaHCO_3) and control salt solution NaCl KCl (147 mM NaCl, 4 mM KCl) and incubated at 37°C for 30 minutes with rotation. InsP_6 -Ca precipitates were observed by phase contrast microscopy. B) 5 nmol of InsP_6 was added to 1 ml of human plasma and incubated at 37°C for the indicated time before acidification and extraction of inositol phosphates with the TiO_2 procedure (Wilson & Saiardi, 2018). The extracts were loaded on 33% polyacrylamide gel and stained with toluidine blue (Lonetti et al., 2011). To orientate the gel polyP100 (50 nmol [Pi]) was loaded on the left and InsP_6 (2 nmol) was used as migration standard. OrangeG (OG) dye was used to monitor gel electrophoresis. C) Albumin and immunoglobulin-depleted male and female plasma (50 mg) were used to perform Western blot with anti Minpp1 antibody. HEK293T and isogenic minpp1^{-/-} extracts (10 mg) (Ucuncu et al., 2020) were used as positive and negative controls respectively. Shown are the representative results of at least three biological repeats.

Description

Inositol phosphates (InsPs) represent a diverse and important class of intracellular signalling molecules (for review see (Kim et al., 2024)). The fully phosphorylated inositol ring of inositol hexakisphosphate (InsP_6) represents the most abundant InsPs present in mammalian cells, with intracellular concentrations ranging from 20 to 100 μM (Qiu et al., 2020; Shears, 2001). InsP_6 not only acts as a structural component of proteins such as the HIV capsid (Mallery et al., 2019) and the RNA-editing deaminase ADAR2 (Macbeth et al., 2005), but also regulates signalling pathways such as necroptosis by activating mixed lineage kinase domain-like ([MLKL](#)) protein (Dovey et al., 2018) and protein phosphorylation by activating casein kinase 2 (CK2) (Solyakov et al., 2004). Additionally, InsP_6 is the main precursor of inositol pyrophosphates such as InsP_7 and InsP_8 , which are important signalling molecules themselves (Nguyen Trung, et al., 2022; Wilson et al., 2013). The charged nature of InsPs prevents their diffusion across the plasma membrane, and therefore, InsPs' metabolic and signalling networks are exclusively intracellular with many InsPs-kinases localized within the cytosol or into the nucleus (Otto et al., 2007; Shears, 2004). We could envisage, however, that cell death mechanisms and subsequent cell lysis could lead to the release of intracellular InsPs to our bloodstream. What is the fate of this theoretical extracellular pool of InsPs? Here we focus our attention on InsP_6 .

Inositol hexakisphosphate possesses a unique charge density, with its twelve negative charges constrained around the carbon backbone of inositol. The biophysical properties of InsP_6 and its association with bivalent cations have been intensively studied (Hager et al., 2016; Kurz et al., 2023). Seminal thermal analysis and solubility measurements studies have determined that in the cytosolic environment, in which magnesium is the prevalent bivalent cation (Romani, 2011), InsP_6 could exist as a soluble penta-magnesium complex up to a concentration of 49 μM (Torres et al., 2005; Veiga et al., 2006). To verify InsP_6 solubility in conditions mimicking the salt composition of the human plasma, we took advantage of two intravenous fluids used to treat dehydration: the glucose-depleted Ringer's solution (147 mM NaCl, 4 mM KCl, 3 mM CaCl_2) and the glucose-depleted Krebs-Ringer's solution (120 mM NaCl, 5 mM KCl, 2 mM CaCl_2 , 1 mM MgCl_2 , 25 mM NaHCO_3) and as a control the same mix of sodium and potassium salts (147 mM NaCl, 4 mM KCl) omitting bivalent cations. Using phase contrast microscopy, we observed the formation of insoluble precipitates when physiological levels of InsP_6 (10 μM and 100 μM) were added to Ringer's or Krebs-Ringer's solution, in a calcium-dependent manner (Figure 1A). Hence, these precipitates must be InsP_6 /Calcium complexes. This qualitative visual result is consistent with the quantitative measurements reporting the insolubility of InsP_6 in solutions containing calcium (Veiga et al., 2006), which is the most prevalent bivalent cation present in plasma (Allgrove, 2009). The prompt precipitation of InsP_6 /Calcium complexes in plasma-mimicking solutions suggests that mammals must have evolved mechanisms to cleanse InsP_6 from plasma, to avoid the formation of harmful precipitates in their circulatory system. Indeed, we previously demonstrated the presence of a robust InsP_6 dephosphorylation activity in mammalian plasma (Irvine et al., 2015; Wilson et al., 2015). Here we repeated the InsP_6 dephosphorylation assay using human plasma samples from both male and female donors. The incubation of InsP_6 (5 μM) in plasma from both genders at 37°C resulted in InsP_6 dephosphorylation over time (Figure 1B), thus confirming previous findings (Irvine et al., 2015; Wilson et al., 2015).

The human genome carries a single gene encoding a phosphatase active towards InsP_6 , namely Multiple Inositol Polyphosphate Phosphatase 1 ([MINPP1](#)). This enzyme belongs to a conserved family of histidine acid phosphatases (IPR016274), commonly referred to as phytases because acting on phytic acid another name for InsP_6 . The thoughtful characterization of [MINPP1](#) enzymatic activities *in vitro* and *in vivo* revealed that this enzyme dephosphorylates InsP_6 primarily to $\text{Ins}(1,2)\text{P}_2$ (Nguyen Trung, Kieninger, et al., 2022). By regulating InsP_6 metabolism, Minpp1 controls numerous cellular processes; additionally, recent Mendelian genetic studies have revealed the importance of [MINPP1](#) in the pathophysiology of a specific form of [pontocerebellar hypoplasia](#) (PCH) (Appelhof et al., 2021; Ucuncu et al., 2020), a severe

neurodegenerative disorder. To verify whether [MINPP1](#) is present in human plasma to account for the observed InsP_6 phosphatase activity (Figure 1B), we utilized an immunochemical assay. To apply this approach to plasma, it is crucial to remove the albumin and immunoglobulins (mainly IgG), which represent about 60% and 20% of the proteome in the plasma, respectively and could interfere with immunoblotting. Using a commercially available albumin and IgG depletion kit we enriched plasma proteome. The western blot performed on the eluate enriched for non-albumin and non-IgG proteins employing anti [MINPP1](#) antibody demonstrates the presence of this critical InsP_6 phosphatase in human plasma (Figure 1C). Our direct analysis confirms a mass spectrometry (MS) based study identifying Minpp1 in human plasma (Farrah et al., 2011). Different sample preparation approaches, MS techniques, and algorithms used to extract MS data could lead to the identification of different sets of proteins from human plasma. In fact, a recent meta-analysis aimed at generating a reference set of plasma proteome to be used for targeted MS does not include [MINPP1](#) (Kliuchnikova et al., 2023). Nevertheless, [MINPP1](#) is one of the 4072 plasma proteins listed by the Human Protein Atlas (<https://www.proteinatlas.org>), here Minpp1 presence is recorded as non-validated by blood-based immunoassay. Our study unequivocally provides this important evidence.

Our confirmation of [MINPP1](#) in human plasma should put to rest the debate on the presence of InsP_6 in plasma (Irvine, 2014; Irvine et al., 2015) that few authors have been able to detect using obviously unreliable analytical methods. The presence of Minpp1 in plasma deemed it unlikely for plasma to contain InsP_6 . Our finding also prompts a reevaluation of the literature that suggest a direct health-beneficial role of orally administrated InsP_6 . Any positive dietary benefit of InsP_6 is likely to have derived from its catabolism to propionate by gut bacteria (De Vos et al., 2024) or from its dephosphorylation to inositol in the gut, which is subsequently absorbed by the intestine.

[MINPP1](#) is predominantly localized inside the endoplasmic reticulum (ER) since it possesses an ER retention signal (KDEL) (Kilaparty et al., 2014; Yu et al., 2023). Secretory vesicles may emerge from ER-Golgi vesicular trafficking pathways which ultimately facilitate the release of [MINPP1](#) into the plasma. Since secretion of KDEL protein has been reported (Palazzo et al., 2022), further studies aimed at characterizing the secretory mechanisms of [MINPP1](#) should be performed to fully appreciate the physiological functions of this important InsP_6 phosphatase outside the cell.

The demonstration of extracellular [MINPP1](#) opens new perspectives to interpret the role of this InsP_6 phosphatase might play in disease conditions (Appelhof et al., 2021; Ucuncu et al., 2020). In the absence of [MINPP1](#), neural cell death could be associated with a release of InsP_6 , leading to InsP_6 /Calcium precipitates in the extracellular space, potentially contributing to pathogenicity. Pathology mechanism could result from a "vicious circle" combining both intra and extracellular deleterious consequences on neural cell differentiation and survival during brain development. Our result raises the possibility of [MINPP1](#)'s presence in the cerebrospinal fluid (CSF). This is a tantalising prospect that warrant the urgent need for further studies in the physiology of [MINPP1](#).

Methods

InsP₆ solubility study.

To study the solubility of InsP_6 , we used three different solutions: glucose-depleted Ringer's solution (147 mM NaCl, 4 mM KCl, 3 mM CaCl_2), glucose-depleted Krebs-Ringer's solution (120 mM NaCl, 5 mM KCl, 2 mM CaCl_2 , 1 mM MgCl_2 , 25 mM NaHCO_3), and a control solution identical to the Ringer's solution but without calcium (147 mM NaCl, 4 mM KCl). InsP_6 was added to each solution at final concentrations of 10 μM and 100 μM . The mixtures were incubated with rotation at 37°C for 30 minutes. Following incubation, samples were examined under a phase contrast microscope (Olympus CX41) to detect the presence of insoluble InsP_6 -Ca precipitates.

InsP₆ dephosphorylation assay.

Male and Female human plasma were bought from TCS Biosciences (Cat: PR200-F-100-H2). Each 1 mL plasma sample was supplemented with a HEPES- MgCl_2 solution to achieve final concentrations of 2 mM HEPES and 1 mM MgCl_2 . InsP_6 (5 μM) (Calbiochem, Sigma-Aldrich, Cat: 407125) was added, and reactions were incubated at 37°C for 20, 60, and 120 minutes. Reactions were stopped by adding 20 μL of a stop solution (100 mM EDTA; 100 mM EGTA). Following incubation, inositol phosphates were purified using the TiO_2 method as previously described (Wilson & Saiardi, 2018) and analysed by polyacrylamide gel electrophoresis PAGE followed by toluidine blue staining (Losito et al., 2009).

Albumin/IgG depletion.

Albumin and IgG were depleted from plasma using the ProteoExtract® Albumin-IgG Removal Kit MAXI (Calbiochem, Sigma-Aldrich, Cat: 122643). Plasma samples were diluted 1:10 in 10X Binding Buffer, and columns were equilibrated with

1X Binding Buffer. The diluted samples were passed through the column, albumin and IgG depleted eluate was collected by washing the column with 2M salt solution as for manufacturer's instructions.

Western Blot Assay.

Plasma samples depleted of IgG and albumin were concentrated and desalted using Amicon® Ultra-0.5 Centrifugal Filter Devices (Millipore, Cat.: UFC501096) according to the manufacturer's protocol. The eluted and concentrated fractions were quantified using the DC™ Protein Assay (Bio-Rad, Reagent A, Cat.: #5000113; Reagent B, Cat.: #5000114; Reagent S, Cat.: #500-0115). Plasma proteins (50 µg) were resolved by electrophoresis using 4-12% Bis-Tris polyacrylamide gels (NuPAGE™, Invitrogen, REF. NP0321BOX) and transferred to nitrocellulose membranes (GE Healthcare Life Sciences Whatman™, Cat.: 10401396). Membranes were blocked in 5% non-fat milk in TBS-T (0.1%) and incubated overnight at 4°C with [MINPP1](#) primary antibody (Santa Cruz, Cat: SC-514214). After three washes in TBS-T (0.1%), membranes were incubated with a secondary anti-mouse IgG1 antibody (Invitrogen, Cat: PA-74421) for 1 hour at room temperature. Detection was performed using the Clarity™ Western ECL substrate (Bio-Rad, Cat.: #170-5060) and images were acquired with the Alliance Q9 imaging system.

Acknowledgements: The authors thank Marcello Gaspari (University Magna Grecia, Italy) for his expert insight on plasma proteome. The authors would like to thank Bessie Xu for reading the manuscript.

References

- Allgrove J. 2009. Physiology of calcium, phosphate and magnesium. *Endocr Dev* 16: 8-31. PubMed ID: [19494658](#)
- Appelhof B, Wagner M, Hoefele J, Heinze A, Roser T, Koch-Hogrebe M, et al., Jamra RA. 2021. Pontocerebellar hypoplasia due to bi-allelic variants in MINPP1. *Eur J Hum Genet* 29(3): 411-421. PubMed ID: [33168985](#)
- De Vos WM, Nguyen Trung M, Davids M, Liu G, Rios-Morales M, Jessen H, et al., Bui TPN. 2024. Phytate metabolism is mediated by microbial cross-feeding in the gut microbiota. *Nat Microbiol* 9(7): 1812-1827. PubMed ID: [38858593](#)
- Dovey CM, Diep J, Clarke BP, Hale AT, McNamara DE, Guo H, et al., Carette JE. 2018. MLKL Requires the Inositol Phosphate Code to Execute Necroptosis. *Mol Cell* 70(5): 936-948.e7. PubMed ID: [29883610](#)
- Farrah T, Deutsch EW, Omenn GS, Campbell DS, Sun Z, Bletz JA, et al., Aebersold R. 2011. A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. *Mol Cell Proteomics* 10(9): M110.006353. PubMed ID: [21632744](#)
- Hager A, Wu M, Wang H, Brown NW Jr, Shears SB, Veiga N, Fiedler D. 2016. Cellular Cations Control Conformational Switching of Inositol Pyrophosphate Analogues. *Chemistry* 22(35): 12406-14. PubMed ID: [27460418](#)
- Irvine RF. 2014. Absence of detectable inositol hexakisphosphate (phytate) in plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 960: 253-4. PubMed ID: [24462526](#)
- Irvine RF, Bulley SJ, Wilson MS, Saiardi A. 2015. There is no 'Conundrum' of InsP6. *Open Biol* 5(11). PubMed ID: [26581573](#)
- Kilaparty SP, Singh A, Baltosser WH, Ali N. 2014. Computational analysis reveals a successive adaptation of multiple inositol polyphosphate phosphatase 1 in higher organisms through evolution. *Evol Bioinform Online* 10: 239-50. PubMed ID: [25574123](#)
- Kim S, Bhandari R, Brearley CA, Saiardi A. 2024. The inositol phosphate signalling network in physiology and disease. *Trends Biochem Sci*. PubMed ID: [39317578](#)
- Kliuchnikova AA, Novikova SE, Ilgisonis EV, Kiseleva OI, Poverennaya EV, Zgoda VG, et al., Ponomarenko EA. 2023. Blood Plasma Proteome: A Meta-Analysis of the Results of Protein Quantification in Human Blood by Targeted Mass Spectrometry. *Int J Mol Sci* 24(1). PubMed ID: [36614211](#)
- Kurz L, Schmieder P, Veiga N, Fiedler D. 2023. One Scaffold, Two Conformations: The Ring-Flip of the Messenger InsP(8) Occurs under Cytosolic Conditions. *Biomolecules* 13(4). PubMed ID: [37189392](#)
- Lonetti A, Szijgyarto Z, Bosch D, Loss O, Azevedo C, Saiardi A. 2011. Identification of an evolutionarily conserved family of inorganic polyphosphate endopolyphosphatases. *J Biol Chem* 286(37): 31966-74. PubMed ID: [21775424](#)
- Losito O, Szijgyarto Z, Resnick AC, Saiardi A. 2009. Inositol pyrophosphates and their unique metabolic complexity: analysis by gel electrophoresis. *PLoS One* 4(5): e5580. PubMed ID: [19440344](#)
- Macbeth MR, Schubert HL, Vandemark AP, Lingam AT, Hill CP, Bass BL. 2005. Inositol hexakisphosphate is bound in the ADAR2 core and required for RNA editing. *Science* 309(5740): 1534-9. PubMed ID: [16141067](#)

Mallery DL, Faysal KMR, Kleinpeter A, Wilson MSC, Vaysburd M, Fletcher AJ, et al., James LC. 2019. Cellular IP(6) Levels Limit HIV Production while Viruses that Cannot Efficiently Package IP(6) Are Attenuated for Infection and Replication. *Cell Rep* 29(12): 3983-3996.e4. PubMed ID: [31851928](#)

Nguyen Trung M, Furkert D, Fiedler D. 2022. Versatile signaling mechanisms of inositol pyrophosphates. *Curr Opin Chem Biol* 70: 102177. PubMed ID: [35780751](#)

Nguyen Trung M, Kieninger S, Fandi Z, Qiu D, Liu G, Mehendale NK, et al., Fiedler D. 2022. Stable Isotopomers of myo-Inositol Uncover a Complex MINPP1-Dependent Inositol Phosphate Network. *ACS Cent Sci* 8(12): 1683-1694. PubMed ID: [36589890](#)

Otto JC, Kelly P, Chiou ST, York JD. 2007. Alterations in an inositol phosphate code through synergistic activation of a G protein and inositol phosphate kinases. *Proc Natl Acad Sci U S A* 104(40): 15653-8. PubMed ID: [17895383](#)

Palazzo FC, Sitia R, Tempio T. 2022. Selective Secretion of KDEL-Bearing Proteins: Mechanisms and Functions. *Front Cell Dev Biol* 10: 967875. PubMed ID: [35912099](#)

Qiu D, Wilson MS, Eisenbeis VB, Harmel RK, Riemer E, Haas TM, et al., Jessen HJ. 2020. Analysis of inositol phosphate metabolism by capillary electrophoresis electrospray ionization mass spectrometry. *Nat Commun* 11(1): 6035. PubMed ID: [33247133](#)

Romani AM. 2011. Cellular magnesium homeostasis. *Arch Biochem Biophys* 512(1): 1-23. PubMed ID: [21640700](#)

Shears SB. 2001. Assessing the omnipotence of inositol hexakisphosphate. *Cell Signal* 13(3): 151-8. PubMed ID: [11282453](#)

Shears SB. 2004. How versatile are inositol phosphate kinases? *Biochem J* 377(Pt 2): 265-80. PubMed ID: [14567754](#)

Solyakov L, Cain K, Tracey BM, Jukes R, Riley AM, Potter BV, Tobin AB. 2004. Regulation of casein kinase-2 (CK2) activity by inositol phosphates. *J Biol Chem* 279(42): 43403-10. PubMed ID: [15297462](#)

Torres J, Domínguez S, Cerdá MF, Obal G, Mederos A, Irvine RF, Díaz A, Kremer C. 2005. Solution behaviour of myo-inositol hexakisphosphate in the presence of multivalent cations. Prediction of a neutral pentamagnesium species under cytosolic/nuclear conditions. *J Inorg Biochem* 99(3): 828-40. PubMed ID: [15708805](#)

Ucuncu E, Rajamani K, Wilson MSC, Medina-Cano D, Altin N, David P, et al., Cantagrel V. 2020. MINPP1 prevents intracellular accumulation of the chelator inositol hexakisphosphate and is mutated in Pontocerebellar Hypoplasia. *Nat Commun* 11(1): 6087. PubMed ID: [33257696](#)

Veiga N, Torres J, Domínguez S, Mederos A, Irvine RF, Díaz A, Kremer C. 2006. The behaviour of myo-inositol hexakisphosphate in the presence of magnesium(II) and calcium(II): protein-free soluble InsP6 is limited to 49 microM under cytosolic/nuclear conditions. *J Inorg Biochem* 100(11): 1800-10. PubMed ID: [16920196](#)

Wilson MS, Bulley SJ, Pisani F, Irvine RF, Saiardi A. 2015. A novel method for the purification of inositol phosphates from biological samples reveals that no phytate is present in human plasma or urine. *Open Biol* 5(3): 150014. PubMed ID: [25808508](#)

Wilson MS, Livermore TM, Saiardi A. 2013. Inositol pyrophosphates: between signalling and metabolism. *Biochem J* 452(3): 369-79. PubMed ID: [23725456](#)

Wilson MS, Saiardi A. 2018. Inositol Phosphates Purification Using Titanium Dioxide Beads. *Bio Protoc* 8(15). PubMed ID: [30148188](#)

Yu J, Leibiger B, Yang SN, Shears SB, Leibiger IB, Berggren PO, Barker CJ. 2023. Multiple Inositol Polyphosphate Phosphatase Compartmentalization Separates Inositol Phosphate Metabolism from Inositol Lipid Signaling. *Biomolecules* 13(6). PubMed ID: [37371464](#)

Funding: The Saiardi's laboratory is supported by Medical Research Council grant MR/T028904/1. Supported by Medical Research Council (United Kingdom) MR/T028904/1 to Saiardi Adolfo .

Author Contributions: Valeria Fedeli: formal analysis, investigation, visualization, writing - review editing. Jingyi Wang: investigation, formal analysis, writing - review editing. Vincent Cantagrel: resources, writing - review editing. Adolfo Saiardi: conceptualization, investigation, supervision, funding acquisition, project administration, writing - original draft, writing - review editing.

Reviewed By: Anonymous

11/1/2024 - Open Access

History: Received October 16, 2024 **Revision Received** October 31, 2024 **Accepted** October 31, 2024 **Published Online** November 1, 2024

Copyright: © 2024 by the authors. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Fedeli, V; Wang, J; Cantagrel, V; Saiardi, A (2024). Human plasma inositol hexakisphosphate (InsP₆) phosphatase identified as the Multiple Inositol Polyphosphate Phosphatase 1 (MINPP1). microPublication Biology. [10.17912/micropub.biology.001390](https://doi.org/10.17912/micropub.biology.001390)